Kyung Dong Pharmaceutical Co., Ltd.

KOSDAQ:A011040 Rapport sur les actions

Capitalisation boursière : ₩170.5b

Kyung Dong Pharmaceutical Croissance future

Future contrôle des critères 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kyung Dong Pharmaceutical.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices38.2%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

None

Dernière mise à journ/a

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Mar 07
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Feb 18
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Feb 03
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 19
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

Jan 04
Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

Dec 20
How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Dec 05
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Kyung Dong Pharmaceutical n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

KOSDAQ:A011040 - Estimations futures des analystes et données financières antérieures (KRW Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/2024178,594-16,191-28,122-18,801N/A
3/31/2024170,232-18,920-24,599-16,145N/A
12/31/2023162,674-20,708-7,999-32N/A
9/30/2023165,7096,480-19,276-3,621N/A
6/30/2023174,1438,366-19,746-5,156N/A
3/31/2023173,1098,422-17,519-3,882N/A
12/31/2022182,71812,161-11,487-1,075N/A
9/30/2022181,7986,5065,8638,711N/A
6/30/2022183,6839,1797,4919,704N/A
3/31/2022185,79312,2918,96211,526N/A
12/31/2021177,61112,6727,68512,422N/A
9/30/2021175,89413,577-19,9914,049N/A
6/30/2021172,33211,669-14,2929,512N/A
3/31/2021171,85311,087-21,7386,344N/A
12/31/2020173,82812,459-11,24417,116N/A
9/30/2020175,09112,91611,63218,460N/A
6/30/2020174,26318,5493,0619,961N/A
3/31/2020176,34820,78811,07313,359N/A
12/31/2019176,50020,126-4,196-2,781N/A
9/30/2019175,9065,751-1892,050N/A
6/30/2019177,8423,1559,61512,950N/A
3/31/2019175,6023,19312,19115,589N/A
12/31/2018179,3165,24229,50433,268N/A
9/30/2018180,11216,91228,15033,220N/A
6/30/2018181,52818,70024,86528,864N/A
3/31/2018181,86120,562N/A27,990N/A
12/31/2017177,77220,477N/A14,788N/A
9/30/2017173,02222,222N/A19,863N/A
6/30/2017166,64019,444N/A19,176N/A
3/31/2017162,70318,670N/A18,588N/A
12/31/2016158,59917,609N/A25,628N/A
9/30/2016155,70518,629N/A24,324N/A
6/30/2016153,07913,673N/A23,802N/A
3/31/2016150,79313,928N/A21,205N/A
12/31/2015151,89314,132N/A18,257N/A
9/30/2015153,19515,395N/A15,456N/A
6/30/2015151,28822,404N/A17,088N/A
3/31/2015153,28622,924N/A20,430N/A
12/31/2014153,26024,518N/A23,130N/A
9/30/2014151,58123,891N/A25,401N/A
6/30/2014148,23625,787N/A22,025N/A
3/31/2014140,86324,591N/A15,381N/A
12/31/2013133,07418,852N/A16,423N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if A011040's forecast earnings growth is above the savings rate (2.6%).

Bénéfices vs marché: Insufficient data to determine if A011040's earnings are forecast to grow faster than the KR market

Croissance élevée des bénéfices: Insufficient data to determine if A011040's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if A011040's revenue is forecast to grow faster than the KR market.

Croissance élevée des revenus: Insufficient data to determine if A011040's revenue is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if A011040's Return on Equity is forecast to be high in 3 years time

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y